Open an account

Puma Biotechnology

PBYI · NASDAQ

$10.76+$0.55 (+5.39%)TodayMarket closed ·
Prev close $10.21

About PBYI

Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 179 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.

Employees
179
Headquarters
Los Angeles, California
Listed
Mar 21, 2012
Sector
Health Care
Industry
Biotechnology
Website
pumabiotechnology.com

PBYI key statistics

Market cap
555.43M
Price-earnings ratio
19.63
Dividend yield
—
Average volume
359.15K
Volume
364.95K
Open price
$10.23
High today
$10.84
Low today
$10.21
52 Week high
$10.72
52 Week low
$4.58

Puma Biotechnology (PBYI) at a glance

As of Oct 20, 2026, Puma Biotechnology (PBYI) shares are priced at $10.76, giving the company a market cap of 555.43M and a price-to-earnings ratio of 19.63.

Today the stock has traded between $10.21 and $10.84. The current price is 5.4% above the day's low and 0.7% below its high.

Volume so far is 364.95K shares, in line with the average of 359.15K shares a day.

Over the past year Puma Biotechnology has ranged from $4.58 to $10.72, and now sits 101% of the way up that range.

Puma Biotechnology met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $0.16 per share against an estimate of $0.0408.

The average analyst price target is $5.10, 52.6% below the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 3 analystsAvg $5.10
Low
$5.05
Now
$10.76
High
$5.25

PBYI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 164.7% on average.

  1. Q3 FY24: reported $0.41 per share against an estimate of $0.3577
  2. Q4 FY24: reported $0.39 per share against an estimate of $0.1047
  3. Q1 FY25: reported $0.06 per share against an estimate of -$0.0204
  4. Q2 FY25: reported $0.12 per share against an estimate of $0.1047
  5. Q3 FY25: reported $0.17 per share against an estimate of $0.0459
  6. Q4 FY25: reported $0.26 per share against an estimate of $0.2315
  7. Q1 FY26: reported -$0.07 per share against an estimate of -$0.1326
  8. Q2 FY26: reported $0.16 per share against an estimate of $0.0408

PBYI news

  • Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript

  • Press releaseBusiness Wire

    Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

  • Press releaseBusiness Wire

    Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference

  • Press releaseBusiness Wire

    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Puma Biotechnology Reports Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

Similar companies

Companies in the same industry as Puma Biotechnology

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.